公开(公告)号：US20240358708A1

公开(公告)日：2024-10-31

申请号：US18649357

申请日：2024-04-29

申请人： Thomas DIACOVO

发明人： Thomas DIACOVO

IPC分类号： A61K31/52 ,  A61K31/573 ,  A61K31/713 ,  C12N9/12 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/573

CPC分类号： A61K31/52 ,  A61K31/573 ,  A61K31/713 ,  C12N9/1205 ,  C12N15/1137 ,  C12Q1/6886 ,  C12Y207/01137 ,  C12Y207/01153 ,  G01N33/5041 ,  G01N33/573

摘要： The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

公开(公告)号：US20240352498A1

公开(公告)日：2024-10-24

申请号：US18751380

申请日：2024-06-24

申请人： The Regents of the University of California ,  Plant Bioscience Limited

发明人： Yuzhong Liu ,  Samantha Aiko Crowe ,  Jay D. Keasling ,  Xiaoyue Chen ,  Graham Arthur Hudson ,  Fei Gan ,  Henrik V. Scheller ,  James Reed ,  Laetitia Martin

IPC分类号： C12P19/60 ,  C12N9/02 ,  C12N9/10 ,  C12N9/12 ,  C12N9/88 ,  C12P5/00

CPC分类号： C12P19/60 ,  C12N9/0069 ,  C12N9/0083 ,  C12N9/1077 ,  C12N9/1205 ,  C12N9/1241 ,  C12N9/88 ,  C12P5/007 ,  C12Y113/99001 ,  C12Y114/99 ,  C12Y207/01043 ,  C12Y207/07064 ,  C12Y402/01076

摘要： The present invention relates inter alia to methods of biosynthetic production of QS-21, precursors and variants thereof, and to related aspects.

公开(公告)号：US20240352497A1

公开(公告)日：2024-10-24

申请号：US17995816

申请日：2021-04-07

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： Thomas F.T. Rexer ,  Reza Mahour

IPC分类号： C12P19/46 ,  C12N9/12 ,  C12N9/14 ,  C12N9/88 ,  C12N9/90

CPC分类号： C12P19/46 ,  C12N9/1205 ,  C12N9/1229 ,  C12N9/1241 ,  C12N9/14 ,  C12N9/88 ,  C12N9/90 ,  C12Y207/01048 ,  C12Y207/04014 ,  C12Y207/07043 ,  C12Y306/01001 ,  C12Y306/01011 ,  C12Y401/03003 ,  C12Y501/03008

摘要： The present invention relates to a method for producing cytidine 5′-monophospho-N-acetyl-neuraminic acid (CMP-Neu5Ac, 1) from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, cytidine and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3). Further, said process may be adapted to produce Neu5Acylated i.e. sialylated biomolecules and biomolecules including a saccharide, a peptide, a protein, a glycopeptide, a glycoprotein, a glycolipid, a glycan, an antibody, and a glycoconjugate, in particular, an antibody drug conjugate, and a carbohydrate conjugate vaccine, or a flavonoid.

公开(公告)号：US20240318206A1

公开(公告)日：2024-09-26

申请号：US18585375

申请日：2024-02-23

申请人： KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Byung-Kwan CHO ,  Donghui CHOE ,  Kang San KIM

IPC分类号： C12P7/04 ,  C12N9/04 ,  C12N9/10 ,  C12N9/12 ,  C12N9/88 ,  C12N9/90 ,  C12N15/70 ,  C12P7/22

CPC分类号： C12P7/04 ,  C12N9/0006 ,  C12N9/1022 ,  C12N9/1205 ,  C12N9/88 ,  C12N9/90 ,  C12N15/70 ,  C12P7/22 ,  C12Y101/01004 ,  C12Y202/01006 ,  C12Y207/01011 ,  C12Y401/01005 ,  C12Y505/01004 ,  C12N2800/101

摘要： The present invention relates to a transcription regulatory biopart based on the 3′-untranslated region and a metabolic flux control method thereof.

公开(公告)号：US12098395B2

公开(公告)日：2024-09-24

申请号：US17255308

申请日：2019-07-19

申请人： Keyangle Life Technology Co., Ltd.

发明人： Yuan'an Wei ,  Xueshu Liu

IPC分类号： C12N9/12 ,  A61K49/00 ,  G01N21/64 ,  G01N21/76 ,  G01N33/569

CPC分类号： C12N9/1205 ,  A61K49/0056 ,  C12Y207/01028 ,  G01N21/6428 ,  G01N21/6458 ,  G01N21/76 ,  G01N33/56966 ,  G01N2021/6439 ,  G01N2333/91215

摘要： The present disclosure relates to a polypeptide recognizing immune cells, the polypeptide includes the following amino acid sequences: (a) an amino acid sequence containing C-terminal fragment sequence EQPDPGAVAAAAILRAILE of human Triokinase/FMN cyclase and its homologous sequence; or (b) an amino acid sequence that is substantially identical to the amino acid sequence described in (a), the substantially identical means 70% or more sequence identity to the amino acid sequence described in (a). The present invention also relates to a nucleic acid sequence encoding the polypeptide; a polypeptide probe used for targeting recognition of immune cells and containing the polypeptide described above and a reporter; a kit containing the probe described above; and, related applications of the polypeptide or probe described above.

公开(公告)号：US20240294951A1

公开(公告)日：2024-09-05

申请号：US18590712

申请日：2024-02-28

申请人： DANISCO US INC.

发明人： Paulus Petrus DE WAAL ,  Jozef Petrus Johannes SCHMITZ ,  Hans Marinus Charles Johannes DE BRUIJN

IPC分类号： C12P7/06 ,  C12N9/02 ,  C12N9/04 ,  C12N9/12 ,  C12N9/88

CPC分类号： C12P7/06 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/1205 ,  C12N9/88 ,  C12Y101/01002 ,  C12Y101/01006 ,  C12Y102/0101 ,  C12Y207/01029 ,  C12Y401/02009

摘要： The invention relates to a recombinant cell, preferably a yeast cell comprising one or more genes coding for an enzyme having glycerol dehydrogenase activity, one or more genes coding dihydroxyacetone kinase (E.C. 2.7.1.28 and/or E.C. 2.7.1.29); one or more genes coding for an enzyme in an acetyl-CoA-production pathway and one or more genes coding for an enzyme having at least NAD+ dependent acetylating acetaldehyde dehydrogenase activity (EC 1.2.1.10 or EC 1.1.1.2), and optionally one or more genes coding for a glycerol transporter. This cell can be used for the production of ethanol and advantageously produces little or no glycerol.

公开(公告)号：US20240287548A1

公开(公告)日：2024-08-29

申请号：US18322618

申请日：2023-05-24

申请人： Jiangnan University

发明人： Chun-Li LIU ,  Eric FORDJOUR ,  Zhonghu BAI ,  Yunpeng HAO ,  Yankun YANG ,  Xiuxia LIU ,  Ye LI ,  Jinling ZHAN

IPC分类号： C12P5/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/10 ,  C12N9/12 ,  C12N15/52

CPC分类号： C12P5/002 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/0093 ,  C12N9/1022 ,  C12N9/1085 ,  C12N9/1205 ,  C12N9/1294 ,  C12N15/52 ,  C12Y101/01028 ,  C12Y101/01049 ,  C12Y102/03003 ,  C12Y102/07001 ,  C12Y117/07001 ,  C12Y202/01007 ,  C12Y205/0101 ,  C12Y207/01002 ,  C12Y207/09002

摘要： The present invention relates to a method for constructing a recombinant bacterium with high production of β-elemene and germacrene A. Firstly, β-elemene and germacrene A are synthesized from scratch through the screening of germacrene A synthase and the overexpression of the mevalonate pathway; then, the availability of acetyl-CoA, pyruvate, and glyceraldehyde-3-phosphate in the farnesyl diphosphate pathway is ensured by deleting competing pathways in the central carbon metabolism; next, the present invention uses lycopene color as a high-throughput screening method and obtains an optimized NSY305N through error-prone PCR. Finally, in shake flasks, strain β-EL-4 constructed through key pathway enzymes, efflux engineering, and translation engineering produced 1161.09 mg/L of β-elemene and 852.36 mg/L of germacrene A, which is the highest reported yield at shake flask level. In 4-L fed-batch fermentation, the production of β-elemene and germacrene A reached 3.52 g/L and 2.13 g/L, respectively.

公开(公告)号：US20240270705A1

公开(公告)日：2024-08-15

申请号：US18563329

申请日：2022-05-25

申请人： Vividion Therapeutics, Inc.

发明人： Benjamin HORNING ,  Nilotpal ROY ,  Matthew PATRICELLI ,  Betty LAM ,  Shota KIKUCHI ,  Brian Nicholas COOK

IPC分类号： C07D265/30 ,  A61K31/40 ,  A61K31/444 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/55 ,  C07D207/08 ,  C07D211/18 ,  C07D211/38 ,  C07D211/42 ,  C07D211/44 ,  C07D223/04 ,  C07D241/04 ,  C07D401/04 ,  C07D401/06 ,  C07D405/06 ,  C12N9/12

CPC分类号： C07D265/30 ,  A61K31/40 ,  A61K31/444 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/55 ,  C07D207/08 ,  C07D211/18 ,  C07D211/38 ,  C07D211/42 ,  C07D211/44 ,  C07D223/04 ,  C07D241/04 ,  C07D401/04 ,  C07D401/06 ,  C07D405/06 ,  C12N9/1205

摘要： Disclosed herein are compounds selective for JAK1, pharmaceutical compositions comprising said compounds, and methods of using said compounds.

公开(公告)号：US12059422B2

公开(公告)日：2024-08-13

申请号：US17845228

申请日：2022-06-21

申请人： MEI Pharma, Inc.

发明人： S. David Brown ,  David J. Matthews

IPC分类号： A61K31/5377 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C12N9/12

CPC分类号： A61K31/5377 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C12N9/1205

摘要： Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

公开(公告)号：US12031138B2

公开(公告)日：2024-07-09

申请号：US16362897

申请日：2019-03-25

申请人： Yeda Research and Development Co. Ltd.

发明人： Ron Milo ,  Niv Antonovsky ,  Elad Noor ,  Arren Bar-Even ,  Yehudit Zohar ,  Lior Zelcbuch ,  Shmuel Gleizer ,  Shira Amram

IPC分类号： C12N15/70 ,  C07K14/195 ,  C07K14/245 ,  C12N1/20 ,  C12N9/04 ,  C12N9/10 ,  C12N9/12 ,  C12N9/88 ,  C12N9/90

CPC分类号： C12N15/70 ,  C07K14/195 ,  C07K14/245 ,  C12N1/20 ,  C12N9/0006 ,  C12N9/1025 ,  C12N9/1205 ,  C12N9/88 ,  C12N9/90 ,  C12Y101/01049 ,  C12Y203/03009 ,  C12Y207/01011 ,  C12Y207/01019 ,  C12Y401/01039 ,  C12Y402/01011 ,  C12Y504/02

摘要： A microorganism which is genetically modified so that it produces a first essential biomass precursor by metabolizing CO2 using a recombinant carbon fixation enzyme is disclosed. The microorganism produces a second biomass precursor by metabolizing an organic carbon source and not by metabolizing CO2. The microorganism does not use the organic carbon source for producing the first essential biomass precursor.